Prima Biomed Ltd (PBMD) 0.83 $PBMD
Prima BioMed doses first subject in Phase 1, first-in-human clinical trial of GSK2831781 for autoimmune diseases, triggering milestone payment
M2 - Fri Jan 30, 2:10AM CST
Biotech company Prima BioMed (ASX
RR) (NASDAQ BMD) reported on Wednesday that the first subject has been dosed in a Phase 1, first-in-human clinical trial of GSK2831781 for the treatment of autoimmune diseases.
PBMD: 0.83 (-0.06)
Prima BioMed to Receive Financial Milestone Payment From GSK
Marketwired - Wed Jan 28, 11:02AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," the "Company"
announces the first dosing of a subject by GSK in a Phase 1, first-in-human clinical trial of a novel depleting anti-LAG-3 antibody (GSK2831781) for the treatment of autoimmune diseases.
PBMD: 0.83 (-0.06)
Prima BioMed wins USD777,000 R&D tax incentive refund from Australia
M2 - Wed Jan 21, 5:54AM CST
Biotech company Prima BioMed (NASDAQ BMD) (ASX RR) disclosed on Tuesday the receipt of USD777,000 cash rebate from the Australian Federal Government's R&D tax incentive programme.
PBMD: 0.83 (-0.06)
Prima BioMed Receives $777K R&D Tax Incentive Refund
Marketwired - Tue Jan 20, 7:54AM CST
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima" is pleased to advise that it has received approximately $777k in a cash rebate from the Australian Federal Government's R&D tax incentive program. The cash rebate was provided essentially in respect of expenditures incurred on eligible Australian R&D activities conducted on the CVac clinical trials during the 2014 financial year.
PBMD: 0.83 (-0.06)
Prima BioMed Receives NASDAQ Notice of Bid Price Deficiency
Marketwired - Mon Dec 29, 6:07AM CST
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company" , announces that it received a notice, dated December 23, 2014 (the "Notice" , from the Listing Qualifications Department of The NASDAQ Stock Market (the "Staff" indicating that, for the period from November 7, 2014 through December 19, 2014, the closing bid price of the Company's American Depositary Shares, or ADS, had not been maintained at the minimum required closing bid price of at least $1.00 per share as required for continued listing on The NASDAQ Global Market pursuant to NASDAQ Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule" .
PBMD: 0.83 (-0.06)
Prima BioMed Announces Immutep's IMP321 Patent Application Receives Canadian Patent Office Notice of Grant
Marketwired - Mon Dec 22, 6:10AM CST
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company" is pleased to announce that it has received a Notice of Grant from the Canadian Patent Office for Patent application CA 2,732,570 entitled "Use of MHC class II Ligands as Adjuvants for Vaccination and of LAG-3 in Cancer Treatment." This patent is licensed from the Institute Gustave Roussy and Merck Serono SA.
PBMD: 0.83 (-0.06)
Prima BioMed Completes Immutep Acquisition
Marketwired - Wed Dec 17, 7:25AM CST
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima" or the "Company" announces that the acquisition of Immutep SA ("Immutep" , the French privately owned biopharmaceutical company in the rapidly growing field of Immuno-Oncology, has been completed.
PBMD: 0.83 (-0.06)
Prima Biomed Enhances CVac Manufacturing and Logistics Capability
Marketwired - Fri Dec 05, 6:55AM CST
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company" announces several enhancements to its CVac manufacturing and logistics infrastructure.
PBMD: 0.83 (-0.06)
CVac Demonstrates Overall Survival Benefit in Second Remission Ovarian Cancer
Marketwired - Thu Nov 06, 6:45AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.83 (-0.06)
Prima BioMed to Host Conference Call & Webcast to Discuss Acquisition of Immutep
Marketwired - Tue Oct 21, 10:15AM CDT
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima" or "the Company" advises that the Company will host a shareholder conference call and webcast to discuss the Company's recent acquisition of French biopharmaceutical company Immutep SA ("Immutep" .
PBMD: 0.83 (-0.06)
Prima BioMed announces Notice of Allowance for LAG-3 Ig (IMP321) in Australia
M2 - Wed Oct 15, 6:47AM CDT
Immunocellular therapeutic company Prima BioMed (ASX RR) (NASDAQ BMD) reported on Tuesday that it has received the Notice of Allowance for "Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response" from the Australian Patent Office.
PBMD: 0.83 (-0.06)
Prima Announces Immutep's IMP321 Patent Application Receives Australian Notice of Allowance
Marketwired - Tue Oct 14, 7:45AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company" is pleased to announce that Immutep S.A. ("Immutep" has received a Notice of Allowance from the Australian Patent Office for Patent Application AU 2008306576 "Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response". As announced on 2 October, 2014 Prima has reached an agreement to acquire Immutep subject to obtaining shareholder approval at its AGM to increase its share placement capacity to fund the acquisition. The AGM will be held on 14 November 2014.
PBMD: 0.83 (-0.06)
Prima Secures US$37.4M Investment Agreement With US Institutional Investor Bergen
Marketwire - Thu Oct 02, 6:01AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.83 (-0.06)
Prima BioMed Announces Strategic Acquisition of Immutep SA
Marketwire - Thu Oct 02, 6:00AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.83 (-0.06)
CVac(TM) CAN-003 Abstract Accepted For Poster Presentation At The Society For Immunotherapy Of Cancer Annual Meeting
PR Newswire - Tue Aug 19, 8:52AM CDT
Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ("Prima", the "Company" today announced that the abstract entitled, "Trial evaluating overall survival in epithelial ovarian cancer (EOC) patients in second remission with an autologous dendritic cell therapy targeting mucin 1" has been accepted for a poster presentation at the Society for Immunotherapy of Cancer ("SITC" 29th Annual Meeting.
PBMD: 0.83 (-0.06)
Prima Receives wins US patent for its personalised immunotherapy CVac
M2 - Thu Jul 17, 7:32AM CDT
Immunocellular therapeutic company Prima BioMed (ASX RR) (NASDAQ BMD) reported on Wednesday the receipt of the US patent number 8,771,701 titled "Compositions for immunotherapy and uses thereof" that protects its CVac technology from the US Patent and Trademark Office (USPTO).
PBMD: 0.83 (-0.06)
Prima Receives US Patent Grant for CVac
Marketwire - Wed Jul 16, 7:20AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company" announces that the US patent number 8,771,701 titled "Compositions for immunotherapy and uses thereof", which protects the Company's CVac(TM) technology, has been granted by the United States Patent and Trademark Office (USPTO).
PBMD: 0.83 (-0.06)
Prima BioMed names Marc Voigt as CEO
M2 - Wed Jul 09, 5:33AM CDT
The board of Prima BioMed (ASX RR) (NASDAQ BMD), a therapeutic company, disclosed on Wednesday the addition of Marc Voigt as its chief executive officer as well as its executive director following the company's recent shift in its operational focus to Europe.
PBMD: 0.83 (-0.06)
Prima BioMed Appoints New Chief Executive Officer
Marketwire - Wed Jul 09, 2:59AM CDT
The Board of Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company" announces that Marc Voigt has today been appointed as Chief Executive Officer of Prima. Mr Voigt, Prima's Chief Business Officer and Chief Financial Officer as well as General Manager of the Company's European Operations, replaces US based Matthew Lehman who will step down from the Board but remain as an adviser to the Company to facilitate an orderly transition.
PBMD: 0.83 (-0.06)
Prima BioMed's CAN-002 CVac(TM) Trial Published in Journal for ImmunoTherapy of Cancer
Marketwire - Mon Jun 23, 7:52AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company" today announced that a research article titled "A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer" was published in the peer-reviewed Journal for ImmunoTherapy of Cancer. Dr. Paul Mitchell is the lead author.
PBMD: 0.83 (-0.06)
Prima BioMed doses first subject in Phase 1, first-in-human clinical trial of GSK2831781 for autoimmune diseases, triggering milestone payment
M2 - Fri Jan 30, 2:10AM CST
Biotech company Prima BioMed (ASX
RR) (NASDAQ BMD) reported on Wednesday that the first subject has been dosed in a Phase 1, first-in-human clinical trial of GSK2831781 for the treatment of autoimmune diseases. PBMD: 0.83 (-0.06)
Prima BioMed to Receive Financial Milestone Payment From GSK
Marketwired - Wed Jan 28, 11:02AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," the "Company"
announces the first dosing of a subject by GSK in a Phase 1, first-in-human clinical trial of a novel depleting anti-LAG-3 antibody (GSK2831781) for the treatment of autoimmune diseases. PBMD: 0.83 (-0.06)
Prima BioMed wins USD777,000 R&D tax incentive refund from Australia
M2 - Wed Jan 21, 5:54AM CST
Biotech company Prima BioMed (NASDAQ
BMD) (ASX RR) disclosed on Tuesday the receipt of USD777,000 cash rebate from the Australian Federal Government's R&D tax incentive programme. PBMD: 0.83 (-0.06)
Prima BioMed Receives $777K R&D Tax Incentive Refund
Marketwired - Tue Jan 20, 7:54AM CST
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima"
is pleased to advise that it has received approximately $777k in a cash rebate from the Australian Federal Government's R&D tax incentive program. The cash rebate was provided essentially in respect of expenditures incurred on eligible Australian R&D activities conducted on the CVac clinical trials during the 2014 financial year. PBMD: 0.83 (-0.06)
Prima BioMed Receives NASDAQ Notice of Bid Price Deficiency
Marketwired - Mon Dec 29, 6:07AM CST
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company"
, announces that it received a notice, dated December 23, 2014 (the "Notice" , from the Listing Qualifications Department of The NASDAQ Stock Market (the "Staff" indicating that, for the period from November 7, 2014 through December 19, 2014, the closing bid price of the Company's American Depositary Shares, or ADS, had not been maintained at the minimum required closing bid price of at least $1.00 per share as required for continued listing on The NASDAQ Global Market pursuant to NASDAQ Listing Rule 5450(a)(1) (the "Minimum Bid Price Rule" . PBMD: 0.83 (-0.06)
Prima BioMed Announces Immutep's IMP321 Patent Application Receives Canadian Patent Office Notice of Grant
Marketwired - Mon Dec 22, 6:10AM CST
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company"
is pleased to announce that it has received a Notice of Grant from the Canadian Patent Office for Patent application CA 2,732,570 entitled "Use of MHC class II Ligands as Adjuvants for Vaccination and of LAG-3 in Cancer Treatment." This patent is licensed from the Institute Gustave Roussy and Merck Serono SA. PBMD: 0.83 (-0.06)
Prima BioMed Completes Immutep Acquisition
Marketwired - Wed Dec 17, 7:25AM CST
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima" or the "Company"
announces that the acquisition of Immutep SA ("Immutep" , the French privately owned biopharmaceutical company in the rapidly growing field of Immuno-Oncology, has been completed. PBMD: 0.83 (-0.06)
Prima Biomed Enhances CVac Manufacturing and Logistics Capability
Marketwired - Fri Dec 05, 6:55AM CST
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company"
announces several enhancements to its CVac manufacturing and logistics infrastructure. PBMD: 0.83 (-0.06)
CVac Demonstrates Overall Survival Benefit in Second Remission Ovarian Cancer
Marketwired - Thu Nov 06, 6:45AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.83 (-0.06)
Prima BioMed to Host Conference Call & Webcast to Discuss Acquisition of Immutep
Marketwired - Tue Oct 21, 10:15AM CDT
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima" or "the Company"
advises that the Company will host a shareholder conference call and webcast to discuss the Company's recent acquisition of French biopharmaceutical company Immutep SA ("Immutep" . PBMD: 0.83 (-0.06)
Prima BioMed announces Notice of Allowance for LAG-3 Ig (IMP321) in Australia
M2 - Wed Oct 15, 6:47AM CDT
Immunocellular therapeutic company Prima BioMed (ASX
RR) (NASDAQ BMD) reported on Tuesday that it has received the Notice of Allowance for "Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response" from the Australian Patent Office. PBMD: 0.83 (-0.06)
Prima Announces Immutep's IMP321 Patent Application Receives Australian Notice of Allowance
Marketwired - Tue Oct 14, 7:45AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company"
is pleased to announce that Immutep S.A. ("Immutep" has received a Notice of Allowance from the Australian Patent Office for Patent Application AU 2008306576 "Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response". As announced on 2 October, 2014 Prima has reached an agreement to acquire Immutep subject to obtaining shareholder approval at its AGM to increase its share placement capacity to fund the acquisition. The AGM will be held on 14 November 2014. PBMD: 0.83 (-0.06)
Prima Secures US$37.4M Investment Agreement With US Institutional Investor Bergen
Marketwire - Thu Oct 02, 6:01AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.83 (-0.06)
Prima BioMed Announces Strategic Acquisition of Immutep SA
Marketwire - Thu Oct 02, 6:00AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.83 (-0.06)
CVac(TM) CAN-003 Abstract Accepted For Poster Presentation At The Society For Immunotherapy Of Cancer Annual Meeting
PR Newswire - Tue Aug 19, 8:52AM CDT
Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ("Prima", the "Company"
today announced that the abstract entitled, "Trial evaluating overall survival in epithelial ovarian cancer (EOC) patients in second remission with an autologous dendritic cell therapy targeting mucin 1" has been accepted for a poster presentation at the Society for Immunotherapy of Cancer ("SITC" 29th Annual Meeting. PBMD: 0.83 (-0.06)
Prima Receives wins US patent for its personalised immunotherapy CVac
M2 - Thu Jul 17, 7:32AM CDT
Immunocellular therapeutic company Prima BioMed (ASX
RR) (NASDAQ BMD) reported on Wednesday the receipt of the US patent number 8,771,701 titled "Compositions for immunotherapy and uses thereof" that protects its CVac technology from the US Patent and Trademark Office (USPTO). PBMD: 0.83 (-0.06)
Prima Receives US Patent Grant for CVac
Marketwire - Wed Jul 16, 7:20AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company"
announces that the US patent number 8,771,701 titled "Compositions for immunotherapy and uses thereof", which protects the Company's CVac(TM) technology, has been granted by the United States Patent and Trademark Office (USPTO). PBMD: 0.83 (-0.06)
Prima BioMed names Marc Voigt as CEO
M2 - Wed Jul 09, 5:33AM CDT
The board of Prima BioMed (ASX
RR) (NASDAQ BMD), a therapeutic company, disclosed on Wednesday the addition of Marc Voigt as its chief executive officer as well as its executive director following the company's recent shift in its operational focus to Europe. PBMD: 0.83 (-0.06)
Prima BioMed Appoints New Chief Executive Officer
Marketwire - Wed Jul 09, 2:59AM CDT
The Board of Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company"
announces that Marc Voigt has today been appointed as Chief Executive Officer of Prima. Mr Voigt, Prima's Chief Business Officer and Chief Financial Officer as well as General Manager of the Company's European Operations, replaces US based Matthew Lehman who will step down from the Board but remain as an adviser to the Company to facilitate an orderly transition. PBMD: 0.83 (-0.06)
Prima BioMed's CAN-002 CVac(TM) Trial Published in Journal for ImmunoTherapy of Cancer
Marketwire - Mon Jun 23, 7:52AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company"
today announced that a research article titled "A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer" was published in the peer-reviewed Journal for ImmunoTherapy of Cancer. Dr. Paul Mitchell is the lead author. PBMD: 0.83 (-0.06)
